Key result
Transdermal estrogen replacement therapy reduced mean nighttime systolic blood pressure by 4.2 mmHg (95% CI -7.7 to -0.7; P=0.039) at 6 months, whereas oral treatment did not significantly alter BP.
Why the study?
Does transdermal estrogen replacement therapy compared to oral estrogen replacement therapy improve ambulatory 24-hour blood pressure in normotensive, oophorectomized women?
Observational (n=90)
Does transdermal estrogen replacement therapy compared to oral estrogen replacement therapy improve ambulatory 24-hour blood pressure in normotensive, oophorectomized women?
Mean Difference: -4.2 (95% CI -7.7–-0.7)
p-value: p=.039
Transdermal, but not oral, estrogen replacement therapy is associated with a reduction in mean ambulatory blood pressure in normotensive oophorectomized women, though individual responses vary.
May favor transdermal estrogen for BP effects in oophorectomized women; leaves open confirmation and outcome impact in randomized trials.
OBJECTIVE: To examine the effects of oral and transdermal estrogen replacement therapy (ERT) on ambulatory 24-hour blood pressure (BP) recordings. METHODS: In a nonrandomized, prospective study, 90 normotensive, oophorectomized women, ages 30-59 years, underwent ambulatory 24-hour BP measurements at study entry and after 3 and 6 months of either oral (n = 50) or transdermal (n = 40) ERT. RESULTS: In the women receiving transdermal estrogen, we observed a change in mean nighttime systolic BP of -4.2 mmHg (95% confidence interval [CI] -7.7, -0.7; P = .039) after 6 months, treatment. There was a change in mean daytime diastolic BP after 3 months (-3.3 mmHg; 95% CI -5.5, -0.9; P = .016) and 6 months (-4 mmHg; 95% CI-6.8, -1.2; P = .014), and in mean nighttime diastolic BP after 3 months (-3.8 mmHg; 95% CI -6.6, -0.9; P = .027) and 6 months (-4.4 mmHg; 95% CI -7.1, -1.7; P = .005). No significant BP changes were observed in the women taking oral estrogen. Although the statistical power to detect a change of 4 mmHg at the 5% significance level was 90% for diastolic BP, it was weaker for systolic BP (63%) in this group. However, in more than one-third of the women receiving either treatment, a statistically significant increase in BP was observed. CONCLUSIONS: Transdermal ERT was associated with a reduction in mean ambulatory BP, whereas oral treatment did not alter BP. Although the overall effect of estrogen was to lower BP, individual responses were variable, and BP increased in more than one-third of the women on either treatment. Therefore, long-term monitoring of ambulatory measurements may be required.
No takes yet. Share an insight, caveat, or question.
A Akkad (1997) conducted an observational in Normotension in oophorectomized women (n=90). Transdermal estrogen replacement therapy vs. Oral estrogen replacement therapy was evaluated on Change in mean nighttime systolic blood pressure at 6 months (MD -4.2, 95% CI -7.7, -0.7, p=.039). Transdermal estrogen replacement therapy reduced mean nighttime systolic blood pressure by 4.2 mmHg (95% CI -7.7 to -0.7; P=0.039) at 6 months, whereas oral treatment did not significantly alter BP.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: